(Press-News.org) ORLANDO, Fla. — Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival, according to Phase III study results presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Patients with advanced colorectal cancer are typically treated with combination chemotherapy with fluorouracil or the derivative product, capecitabine with or without levofolinic acid with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) given alone, or with the monoclonal antibodies bevacizumab, cetuximab or panitumumab.
"These combinations have been successful in inducing tumor regression, retarding disease progression and increasing overall survival. However, the average progression-free survival and overall survival are still no more than eight to 10 months and 20 to 22 months, respectively," said Pierpaolo Correale, M.D., Ph.D., an oncologist at the Siena University School of Medicine in Italy.
This study was started in 2005, before monoclonal antibodies were routinely used. Correale and colleagues added gemcitabine to FOLFOX followed by granulocyte-macrophage colony stimulating factor and low-dose aldesleukine (GOLFIG) to boost the immune system in an effort to fight cancer.
The researchers randomized 130 patients to receive GOLFIG or FOLFOX for a maximum of 12 cycles and then receive maintenance treatment until disease progression. The study was designed to follow the patients in both arms until death, but was ended early due to significantly better results seen with the GOLFIG regimen.
So far, the patients who received GOLFIG had a progression-free survival of 16.5 months compared with the 7.5 months recorded in those patients who received FOLFOX.
"Based on our experience and results to date, we believe that the GOLFIG regimen is superior to FOLFOX chemotherapy in terms of efficacy and comparable in terms of toxicity and cost," said Correale. "We were very surprised to find such a significant difference in terms of overall survival with this low number of patients."
The challenge for the future will be to compare GOLFIG regimen with regimens containing monoclonal antibodies, he said.
###
Press registration for the AACR 102nd Annual Meeting 2011 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
GOLFIG increased progression-free survival in colorectal cancer patients
2011-04-07
ELSE PRESS RELEASES FROM THIS DATE:
Physical health scores predict breast cancer outcomes
2011-04-07
ORLANDO, Fla. — Breast cancer survivors with poor physical health scores had an elevated risk of poorer cancer outcomes, including recurrence and death, according to the results of an observational study presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
Survivors of breast cancer who had poor health scores were 27 percent more likely to experience either a recurrence of their cancer or a new breast cancer. Physical health also impacted survival quite strongly; risk of death from any cause was 65 percent greater among those with poorer health scores.
Researchers ...
Strawberries may slow precancerous growth in esophagus
2011-04-07
ORLANDO, Fla. — Freeze-dried strawberries may be an alternative to drugs for the prevention of esophageal cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
"We concluded from this study that six months of eating strawberries is safe and easy to consume. In addition, our preliminary data suggests that strawberries can decrease histological grade of precancerous lesions and reduce cancer-related molecular events," said lead researcher Tong Chen, M.D., Ph.D., assistant professor, division of medical oncology, department ...
Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen
2011-04-07
ORLANDO, FL (April 6, 2011) – Breast cancer is the second most common cancer among women, with more than 200,000 women diagnosed each year. Being exposed to estrogen over a long period of time is one factor that can increase a woman's risk of developing the disease. One way a woman can combat this risk factor is by taking the breast cancer drug tamoxifen, which interferes with the activity of estrogen. Now, researchers at Fox Chase Cancer Center have found that omega-3 fatty acids—abundant in fish—could be a safe and beneficial booster for tamoxifen therapy.
Jose Russo, ...
Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer
2011-04-07
ORLANDO, FL (April 6, 2011) – Numerous studies show that non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colon cancer. However, animal studies testing the NSAID naproxen or its derivative, NO-naproxen, have focused primarily on chemically-induced tumor formation. Now, researchers at Fox Chase Cancer Center find that naproxen and NO-naproxen reduce tumor formation in a strain of mutant mice that spontaneously develop colon tumors. The data also suggest that naproxen blocks a gatekeeper step that initiates tumor formation.
Margie Clapper, PhD, Co-Leader ...
Healthy welders may be at increased risk for early brain damage
2011-04-07
New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Fumes produced by welding contain manganese. Manganese is a chemical element that, even at low levels, has been linked to neurologic problems, including Parkinson's disease-like symptoms.
"There are over one million workers who perform welding as part of their job functions ...
Genetic variants associated with caffeine intake identified
2011-04-07
Two genes in which variation affects intake of caffeine, the most widely consumed stimulant in the world, have been discovered. A team of investigators from the National Cancer Institute, Harvard School of Public Health, Brigham and Women's Hospital, and the University of North Carolina at Chapel Hill examined genetic variation across the entire genome of more than 47,000 individuals from the U.S., as described in the open-access journal PLoS Genetics.
The genes identified were CYP1A2, which has previously been implicated in the metabolism of caffeine, and AHR, involved ...
An international study in China finds strawberries may slow precancerous growth in the esophagus
2011-04-07
COLUMBUS, Ohio – Eating strawberries may be a way to help people at risk of esophageal cancer protect themselves from the disease, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and researchers in China.
Dr. Tong Chen will present the findings during a press briefing at 8 a.m. April 6 at the American Association for Cancer Research (AACR) 102nd meeting 2011 in Orlando, Fla. The study is the first-ever collaborative Ohio State cancer ...
Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists
2011-04-07
The United States should pay close attention to how the United Kingdom carries out plans to assess a new drug's worth using factors that go beyond clinical and cost effectiveness, according to researchers at the Johns Hopkins Berman Institute of Bioethics.
In a commentary to appear in the April 7 issue of the New England Journal of Medicine, the bioethicists detail and discuss a new, "value-based pricing" policy proposed by the British government. Up to now, companies have been able to price their drugs freely. But if the new policy is implemented, the U.K. will start ...
NYU Cancer Institute experts present at the AACR 102nd Annual Meeting 2011
2011-04-07
Experts from The Cancer Institute at NYU Langone Medical Center presented new research findings at the American Association for Cancer Research 102nd Annual Meeting 2011 held April 2-6, 2011 in Orlando, Florida. NYU Cancer Institute researchers discussed various breakthroughs such as a novel test for early-stage asbestos-related pulmonary cancer, a promising treatment strategy for glioblastomas, genome-wide mapping of nickel-related cancer and greater understanding of melanoma and bladder cancer.
Detection of Mesothelioma in Asbestos Exposed Individuals with Aptamer ...
Trion:Z Announces Masters Tournament Active Series Contest
2011-04-07
To participate in the Trion:Z Masters Tournament giveaway contest, all you have to do is pick which of the three Rs is going to win. Trion:Z's triple threat; Rickie Fowler, Rory Mc Ilroy and Ryo Ishikawa - all will be competing for the coveted green jacket. Each possess the skill, talent, and drive to be the next Masters Champion.
According to Reuters' Mark Lamport-Stokes, "Mc Ilroy long regarded as a future world #1 is probably the most spectacular member of the emerging generation to watch." However, Ishikawa is playing for the pride of Japan and is donating his 2011 ...